Serum human epididymis protein 4 levels in colorectal cancer patients

Kemal,Yasemi̇n; Demi̇rag,Guzi̇n; Bedi̇r,Abdulkeri̇m; Tomak,Leman; Derebey,Murat; Erdem,Di̇lek; Gör,Ufuk; Yücel,Idris

doi:10.3892/mco.2017.1332

Serum human epididymis protein 4 levels in colorectal cancer patients

Authors:
- Yasemi̇n Kemal
- Guzi̇n Demi̇rag
- Abdulkeri̇m Bedi̇r
- Leman Tomak
- Murat Derebey
- Di̇lek Erdem
- Ufuk Gör
- Idris Yücel
View Affiliations

Affiliations: Department of Medical Oncology, Samsun Training and Research Hospital, Samsun 55100, Turkey, Department of Medical Oncology, Faculty of Medicine, Ondokuz Mayis University, Samsun 55270, Turkey, Department of Biochemistry, Faculty of Medicine, Ondokuz Mayis University, Samsun 55270, Turkey, Department of Biostatistics, Faculty of Medicine, Ondokuz Mayis University, Samsun 55270, Turkey, Department of General Surgery, Faculty of Medicine, Ondokuz Mayis University, Samsun 55270, Turkey, Department of Medical Oncology, Medical Park Samsun Hospital, Samsun 55200, Turkey, Department of Biochemistry, Faculty Of Medicine, Ondokuz Mayis University, Samsun 55270, Turkey, Department of Medical Oncology, Faculty Of Medicine, Ondokuz Mayis University, Samsun 55270, Turkey
Published online on: July 19, 2017 https://doi.org/10.3892/mco.2017.1332
Pages: 481-485

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Tumour markers are widely used for the diagnosis, staging and monitoring of colorectal cancer (CRC) patients in clinical practice. Carcinoembryonic antigen (CEA) and carbohydrate antigen 19‑9 (CA19‑9) are the most frequently used biomarkers in CRC patients. A number of studies have recently investigated the presence of human epididymis protein 4 (HE4) overexpression in certain cancer types. Its significance in ovarian and endometrial cancer has been well‑demonstrated. The aim of the present study was to evaluate the significance of serum HE4 levels in CRC patients. A total of 46 newly diagnosed CRC patients and 36 age‑ and gender‑matched healthy subjects were included in the study. The concentrations of CEA and CA19‑9 were also determined and compared according to HE4 levels. HE4 positivity was determined in 13 of the 46 cases (28.3%) in the CRC group, but no HE4‑positive subjects were identified in the control group (0%; P=0.009). The area under the receiver operating characteristic curve for HE4 positivity was 0.641 (95% CI: 0.523‑0.760). HE4 was statistically significantly positive in patients with stage III‑IV disease and in those with high CA 19‑9 levels (all P<0.01). To the best of our knowledge, this is the first study to investigate HE4 expression in CRC patients, and the findings suggest that it may be a useful biomarker, particularly in stage III‑IV patients.

View Figures

View References

1	Labianca R, Nordlinger B, Beretta GD, Mosconi S, Mandalà M, Cervantes A and Arnold D: ESMO Guidelines Working Group: Early colon cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 24 Suppl 6:vi64–vi72. 2013. View Article : Google Scholar : PubMed/NCBI
2	World Cancer Report 2014. World Health Organization. Chapter 1.1. 2014
3	Welch JP and Donaldson GA: The clinical correlation of an autopsy study of recurrent colorectal cancer. Ann Surg. 189:496–502. 1979.PubMed/NCBI
4	Borner MM: Neoadjuvant chemotherapy for unresectable liver metastases of colorectal cancer-too good to be true? Ann Oncol. 10:623–326. 1999. View Article : Google Scholar : PubMed/NCBI
5	Pamies RJ and Crawford DR: Tumor markers. An update. Med Clin North Am. 80:185–199. 1996. View Article : Google Scholar : PubMed/NCBI
6	Perkins GL, Slater ED, Sanders GK and Prichard JG: Serum tumor markers. Am Fam Physician. 68:1075–1082. 2003.PubMed/NCBI
7	Clinical practice guidelines for the use of tumor markers in breast and colorectal cancer. Adopted on May 17, 1996 by the American Society of Clinical Oncology. J Clin Oncol. 14:2843–2877. 1996. View Article : Google Scholar : PubMed/NCBI
8	Fletcher RH: Carcinoembryonic antigen. Ann Intern Med. 104:66–73. 1986. View Article : Google Scholar : PubMed/NCBI
9	Gupta MK, Arciaga R, Bocci L, Tubbs R, Bukowski R and Deodhar SD: Measurement of a monoclonal-antibody-defined antigen (CA19-9) in the sera of patients with malignant and nonmalignant diseases. Comparison with carcinoembryonic antigen. Cancer. 56:277–283. 1985. View Article : Google Scholar : PubMed/NCBI
10	Kirchhoff C, Habben I, Ivell R and Krull N: A major human epididymis-specific cDNA encodes a protein with sequence homology to extracellular proteinase inhibitors. Biol Reprod. 45:350–357. 1991. View Article : Google Scholar : PubMed/NCBI
11	Drapkin R, von Horsten HH, Lin Y, Mok SC, Crum CP, Welch WR and Hecht JL: Human epididymis protein 4 (HE4) is a secreted glycoprotein that is overexpressed by serous and endometrioid ovarian carcinomas. Cancer Res. 65:2162–2169. 2005. View Article : Google Scholar : PubMed/NCBI
12	Galgano MT, Hampton GM and Frierson HF Jr: Comprehensive analysis of HE4 expression in normal and malignant human tissues. Mod Pathol. 19:847–853. 2006.PubMed/NCBI
13	Kirchhoff C: Molecular characterization of epididymal proteins. Rev Reprod. 3:86–95. 1998. View Article : Google Scholar : PubMed/NCBI
14	Clauss A, Lilja H and Lundwall A: A locus on human chromosome 20 contains several genes expressing protease inhibitor domains with homology to whey acidic protein. Biochem J. 368:233–242. 2002. View Article : Google Scholar : PubMed/NCBI
15	Thompson RC and Ohlsson K: Isolation, properties, and complete amino acid sequence of human secretory leukocyte protease inhibitor, a potent inhibitor of leukocyte elastase. Proc Natl Acad Sci USA. 83:6692–6696. 1986. View Article : Google Scholar : PubMed/NCBI
16	Plebani M: HE4 Study Group: HE4 in gynecological cancers: Report of a European investigators and experts meeting. Clin Chem Lab Med. 50:2127–2136. 2012. View Article : Google Scholar : PubMed/NCBI
17	Brennan DJ, Hackethal A, Metcalf AM, Coward J, Ferguson K, Oehler MK, Quinn MA, Janda M, Leung Y, Freemantle M, et al: Serum HE4 as a prognostic marker in endometrial cancer-a population based study. Gynecol Oncol. 132:159–165. 2014. View Article : Google Scholar : PubMed/NCBI
18	Yang Z, Luo Z, Zhao B, Zhang W, Zhang J, Li Z and Li L: Diagnosis and preoperative predictive value of serum HE4 concentrations for optimal debulking in epithelial ovarian cancer. Oncol Lett. 6:28–34. 2013.PubMed/NCBI
19	Simmons AR, Baggerly K and Bast RC Jr: The emerging role of HE4 in the evaluation of epithelial ovarian and endometrial carcinomas. Oncology (Williston Park). 27:548–556. 2013.PubMed/NCBI
20	Yu S, Yang HJ, Xie SQ and Bao YX: Diagnostic value of HE4 for ovarian cancer: A meta-analysis. Clin Chem Lab Med. 50:1439–1446. 2012. View Article : Google Scholar : PubMed/NCBI
21	Lin J, Qin J and Sangvatanakul V: Human epididymis protein 4 for differential diagnosis between benign gynecologic disease and ovarian cancer: A systematic review and meta-analysis. Eur J Obstet Gynecol Reprod Biol. 167:81–85. 2013. View Article : Google Scholar : PubMed/NCBI
22	Hellstrom I, Raycraft J, Hayden-Ledbetter M, Ledbetter JA, Schummer M, McIntosh M, Drescher C, Urban N and Hellström KE: The HE4 (WFDC2) protein is a biomarker for ovarian carcinoma. Cancer Res. 63:3695–3700. 2003.PubMed/NCBI
23	Zhen S, Bian LH, Chang LL and Gao X: Comparison of serum human epididymis protein 4 and carbohydrate antigen 125 as markers in ovarian cancer: A meta-analysis. Mol Clin Oncol. 2:559–566. 2014.PubMed/NCBI
24	Iwahori K, Suzuki H, Kishi Y, Fujii Y, Uehara R, Okamoto N, Kobayashi M, Hirashima T, Kawase I and Naka T: Serum HE4 as a diagnostic and prognostic marker for lung cancer. Tumour Biol. 33:1141–1149. 2012. View Article : Google Scholar : PubMed/NCBI
25	Nagy B Jr, Bhattoa HP, Steiber Z, Csobán M, Szilasi M, Méhes G, Müller M, Lázár J, Kappelmayer J and Antal-Szalmás P: Serum human epididymis protein 4 (HE4) as a tumor marker in men with lung cancer. Clin Chem Lab Med. 52:1639–1648. 2014. View Article : Google Scholar : PubMed/NCBI
26	Guo YD, Wang JH, Lu H, Li XN, Song WW and Zhang XD: The human epididymis protein 4 acts as a prognostic factor and promotes progression of gastric cancer. Tumour Biol. 36:2457–2464. 2015. View Article : Google Scholar : PubMed/NCBI